Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: A critical view

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 6, 1997, Pages 465-473

  Mahmood, Iftekhar ^a  

^a Woodmont Office Center II   (United States)

Author keywords

Absolute bioavailability; Oral clearance; Renal clearance; Renal dysfunction

Indexed keywords

ACEBUTOLOL; AMILORIDE; ATENOLOL; CIBENZOLINE; ENOXACIN; FLECAINIDE ACETATE; RANITIDINE; TIOPRONIN;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXCRETION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PREDICTION;

ACEBUTOLOL; ADMINISTRATION, ORAL; ADULT; AGED; AMILORIDE; ANTI-ARRHYTHMIA AGENTS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; ATENOLOL; BIOLOGICAL AVAILABILITY; DIURETICS; ENOXACIN; FLECAINIDE; HISTAMINE H2 ANTAGONISTS; HUMANS; IMIDAZOLES; KIDNEY; KIDNEY FAILURE; MIDDLE AGED; RANITIDINE; THIOPRONINE;

EID: 0030854675     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199708)18:6<465::AID-BDD41>3.0.CO;2-C     Document Type: Article

References (22)

1. M. Gibaldi, R. N. Boyes and S. Feldman, Influence of first pass effect on availability of drugs on oral administration. J. Pharm. Sci., 60, 1338 (1971).
2. D. Lalka and H. Feldman, Absolute drug bioavailability. Approximation without comparison to parenteral dose for compounds exhibiting peturbable renal clearance. J. Pharm. Sci., 63, 1812 (1974).
3. P. H. Hindeling and J. Shi, Absolute bioavailability estimated from oral data. J. Pharm. Sci., 84, 385 (1995).
4. R. K. Nayak, L. G. Gisclon, C. A. Curtin and L. Z. Benet, Estimation of the absolute bioavailability of topiramate in humans without intravenous data. J. Clin. Pharmacol., 34, 1029 (1994).
5. J. Braun, J. R. Kollert and J. U. Becker, Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. Eur. J. Clin. Phamacol., 31, 711 (1987).
6. A. G. Gilman, W. T. Rall, A. S. Nies and P. Taylor (Eds), The Pharmacological Basis of Therapeutics, 8th edn, Pergamon, New York. 1990.
7. A. J. Williams, R. L. McQuinn and J. Walls, Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin. Pharmacol. Ther., 43, 449 (1988).
8. N. P. Chau, P. Y. Zech, N. Pozet and A. Hadj-Aissa, Ranitidine kinetics in normal subjects. Clin. Pharmacol. Ther., 31, 770 (1982).
9. D. C. Garg, N. Baltodano, N. S. Jallad, G. Perez, J. R. Oster, F. N. Eshelman and D. J. Weidler, Pharmacokinetics of ranitidine in patients with renal failure. J. Clin. Pharmacol., 26, 286 (1986).
10. W. D. Mason, N. Winer, G. Kochak, I. Cohen and R. Bell, Kinetics and absolute bioavailability of atenolol. Clin. Pharmacol. Ther., 25, 408 (1979).
11. J. McAinsh, B. F. Holmes, S. Smith, D. Hood and D. Warren, Atenolol kinetics in renal failure. Clin. Pharmacol. Ther., 28, 302 (1980).
12. J. W. Massarella, K. C. Khoo, K. Aogaichi, D. Persio, M. Smith, J. Kluger and M. Chow, Effect of renal impairment on the pharmacokinetics of cibenzoline. Clin. Pharmacol. Ther., 43, 317 (1988).
13. J. W. Massarella, T. Silvestri and A. Lin, Relative and absolute bioavailability of cibenzoline capsules and tablets in healthy volunteers. J. Pharm. Sci., 75, 894 (1986).
14. A. Roux, P. Aubert, J. Guedon and B. Flouvat, Pharmacokinetics of acebutalol in patients with all grades of renal failure. Eur. J. Clin. Pharmacol., 17, 339 (1980).
15. R. W. Bury, G. J. Becker, P. S. Kincaid-Smith, R. F. W. Moulds and J. A. Whitworth, Elimination of enoxacin in renal disease. Clin. Pharmacol. Ther., 41, 434 (1987).
16. M. S. Carlsson, T. Denneberg, B. M. Emanuelsson, B. Kagedal and S. Lindgren, Pharmacokinetics of oral tiopronin. Eur. J. Clin. Pharmacol., 45, 79 (1993).
17. M. S. Carlsson, T. Denneberg, B. M. Emanuelsson, B. Kagedal and S. Lindgren, Pharmacokinetics of 2-mercaptopropionylglycine (tiopronin) in patients with impaired renal function. Drug. Invest., 7, 101 (1994).
18. H. Spahn, K. Reuter, E. Mutschler, W. Gerok and H. Knauf, Pharmacokinetics of amiloride in renal and hepatic disease. Eur. J. Clin. Pharmacol., 33, 493 (1987).
19. E. E. Ohnhaus, S. Vozeh and E. Nuesch, Absolute bioavailability of digoxin in chronic renal failure. Clin. Nephrol., 11, 302 (1979).
20. D. T. Lowenthal, W. A. Briggs, T. P. Gibson, H. Nelson and W. J. Cirkesena, Pharmacokinetics of oral propranolol in chronic renal disease. Clin. Pharmacol. Ther., 16, 761 (1974).
21. J. Fabre and L. Balant, Renal failure, drug pharmacokinetics and drug action. Clin. Pharmacokinet., 1, 99 (1976).
22. W. J. Tilstone and A. Fine, Furosemide kinetics in renal failure. Clin. Pharmacol. Ther., 23, 644 (1978).